

Obesity, Diabetes, and Risk of Prostate Cancer: Results of the Cancer Prevention Trial

Cancer Epidemiology Biomarkers and Prevention
15, 1977-1983

DOI: [10.1158/1055-9965.epi-06-0477](https://doi.org/10.1158/1055-9965.epi-06-0477)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anthropometrics and Prostate Cancer Risk. American Journal of Epidemiology, 2007, 165, 1271-1279.	3.4	74
2	The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nature Reviews Urology, 2007, 4, 605-614.	1.4	36
3	Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiologic Reviews, 2007, 29, 88-97.	3.5	199
4	Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12936-12941.	7.1	21
5	The Food Frequency Questionnaire. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 182-183.	2.5	42
6	Obesity and prostate cancer mortality. Future Oncology, 2007, 3, 557-567.	2.4	26
10	Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 63-69.	2.5	300
11	Association of Body Mass Index With Response and Survival in Men With Metastatic Prostate Cancer: Southwest Oncology Group Trials 8894 and 9916. Journal of Urology, 2007, 178, 1946-1951.	0.4	30
12	The Role of Obesity and Related Metabolic Disturbances in Cancers of the Colon, Prostate, and Pancreas. Gastroenterology, 2007, 132, 2208-2225.	1.3	483
13	Obesity, metabolic syndrome, and prostate cancer. American Journal of Clinical Nutrition, 2007, 86, 843S-857S.	4.7	291
14	Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer, 2007, 109, 1192-1202.	4.1	142
15	Obesity and mortality in men with locally advanced prostate cancer. Cancer, 2007, 110, 2691-2699.	4.1	86
16	Chemoprevention of prostate cancer: lessons learned. BJU International, 2007, 100, 15-17.	2.5	5
17	Obesity and Prostate Cancer: Epidemiology and Clinical Implications. European Urology, 2007, 52, 331-343.	1.9	209
18	Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia. Cancer Causes and Control, 2007, 18, 375-384.	1.8	11
19	A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden). Cancer Causes and Control, 2007, 18, 1107-1121.	1.8	68
20	Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes and Control, 2008, 19, 703-710.	1.8	47
21	Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes and Control, 2008, 19, 793-803.	1.8	36

#	ARTICLE	IF	CITATIONS
22	Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Cancer Causes and Control</i> , 2008, 19, 1267-1276.	1.8	79
23	A genetic link between type 2 diabetes and prostate cancer. <i>Diabetologia</i> , 2008, 51, 1757-1760.	6.3	96
24	Finasteride, prostate cancer, and weight gain: Evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. <i>Prostate</i> , 2008, 68, 281-286.	2.3	6
25	Prostate cancer incidence among American Indian and Alaska Native men, US, 1999-2004. <i>Cancer</i> , 2008, 113, 1203-1212.	4.1	28
26	Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 172-177.	4.4	84
27	Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. <i>BJU International</i> , 2008, 101, 313-318.	2.5	92
28	Body Composition and Serum Prostate-Specific Antigen: Review and Findings from Flint Men's Health Study. <i>Urology</i> , 2008, 71, 554-560.	1.0	33
29	Obesity Is a Significant Risk Factor for Prostate Cancer at the Time of Biopsy. <i>Urology</i> , 2008, 72, 1102-1105.	1.0	79
30	c-Jun NH2-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 593-604.	3.8	38
31	Glycemic Status and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 628-635.	2.5	22
32	Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 3252-3261.	2.5	104
33	Variants in circadian genes and prostate cancer risk: a population-based study in China. <i>Prostate Cancer and Prostatic Diseases</i> , 2008, 11, 342-348.	3.9	93
34	Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men. <i>Prostate Cancer and Prostatic Diseases</i> , 2008, 11, 264-269.	3.9	30
35	Prevention of Prostate Cancer: What We Know and Where We Are Going. <i>American Journal of Men's Health</i> , 2008, 2, 178-189.	1.6	7
36	Obesity and cancer. <i>Proceedings of the Nutrition Society</i> , 2008, 67, 128-145.	1.0	258
37	A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. <i>British Journal of Cancer</i> , 2009, 100, 1799-1805.	6.4	73
38	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	6.3	328
39	Association of Diabetes With Prostate Cancer Risk in the Multiethnic Cohort. <i>American Journal of Epidemiology</i> , 2009, 169, 937-945.	3.4	136

#	ARTICLE	IF	CITATIONS
40	Relationship of Body Mass, Height, and Weight Gain to Prostate Cancer Risk in the Multiethnic Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2413-2421.	2.5	43
41	Dietary Supplement Use and Prostate Cancer Risk in the Carotene and Retinol Efficacy Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2202-2206.	2.5	76
42	Use of Thiazolidinediones Does Not Affect Prostate-Specific Antigen Levels in Men with Diabetes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1937-1938.	2.5	3
43	Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1350-1356.	2.5	55
44	Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. <i>Prostate Cancer and Prostatic Diseases</i> , 2009, 12, 259-263.	3.9	124
45	Effect of Population Trends in Body Mass Index on Prostate Cancer Incidence and Mortality in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 808-815.	2.5	25
46	Birth Characteristics and Risk of Prostate Cancer: the Contribution of Genetic Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2422-2426.	2.5	23
47	Prostate cancer is associated with the metabolic syndrome. <i>Journal of Men's Health</i> , 2009, 6, 125-129.	0.3	3
48	Is There Evidence of a Relationship between Benign Prostatic Hyperplasia and Prostate Cancer? Findings of a Literature Review. <i>European Urology</i> , 2009, 55, 864-875.	1.9	174
49	Obesity as a predictor of adverse outcome across black and white race. <i>Cancer</i> , 2009, 115, 5263-5271.	4.1	66
50	Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?. <i>BJU International</i> , 2009, 103, 877-882.	2.5	21
51	The effect of obesity and lower serum prostate-specific antigen levels on prostate cancer screening results in American men. <i>BJU International</i> , 2009, 104, 1457-1461.	2.5	43
52	Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. <i>International Journal of Cancer</i> , 2009, 124, 1398-1403.	5.1	153
53	Risk factors for prostate cancer. <i>Nature Reviews Urology</i> , 2009, 6, 87-95.	1.4	112
54	Muscle atrophy in cancer: a role for nutrition and exercise. <i>Applied Physiology, Nutrition and Metabolism</i> , 2009, 34, 950-956.	1.9	11
55	The Impact of Obesity on Overall and Cancer Specific Survival in Men With Prostate Cancer. <i>Journal of Urology</i> , 2009, 182, 112-117.	0.4	29
56	Obesity and Prostate Cancer: An Insight Into Postmodern Medicine. <i>Journal of Urology</i> , 2009, 182, 14-15.	0.4	10
57	The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. <i>European Journal of Cancer Prevention</i> , 2010, 19, 256-271.	1.3	37

#	ARTICLE	IF	CITATIONS
58	The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. <i>Journal of Cancer Survivorship</i> , 2010, 4, 128-139.	2.9	126
59	Medical history, body size, and cigarette smoking in relation to fatal prostate cancer. <i>Cancer Causes and Control</i> , 2010, 21, 117-125.	1.8	16
60	Body size and risk of prostate cancer in Jamaican men. <i>Cancer Causes and Control</i> , 2010, 21, 909-917.	1.8	17
61	History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. <i>Cancer Causes and Control</i> , 2010, 21, 1025-1032.	1.8	64
62	The relation between adiposity throughout the life course and variation in IGFs and IGFBNs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010, 21, 1829-1842.	1.8	26
63	Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. <i>International Journal of Cancer</i> , 2010, 127, 1660-1668.	5.1	56
64	<i>HNF1B</i> and <i>JAZF1</i> genes, diabetes, and prostate cancer risk. <i>Prostate</i> , 2010, 70, 601-607.	2.3	45
65	Association between C-Peptide Concentration and Prostate Cancer Incidence in the CLUE II Cohort Study. <i>Cancer Prevention Research</i> , 2010, 3, 1334-1341.	1.5	18
66	Obesity, Endogenous Hormone Metabolism, and Prostate Cancer Risk: A Conundrum of "Highs" and "Lows". <i>Cancer Prevention Research</i> , 2010, 3, 259-262.	1.5	25
67	Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2010, 3, 279-289.	1.5	33
68	Obesity and Cancer Epidemiology. , 2010, , 1-44.		12
69	Diabetes Genes and Prostate Cancer in the Atherosclerosis Risk in Communities Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 558-565.	2.5	48
70	2157 THE ASSOCIATION OF DIABETES MELLITUS AND HIGH-GRADE PROSTATE CANCER IN A MULTIETHNIC BIOPSY SERIES. <i>Journal of Urology</i> , 2010, 183, .	0.4	0
71	Higher Body Mass Index Is Associated With Lower Risk of Prostate Cancer Detection Via Multi (â%¥12)-Core Prostate Biopsy in Korean Men. <i>Urology</i> , 2010, 76, 1063-1066.	1.0	13
72	Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 362-368.	3.9	44
73	2011 and beyond. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 1-2.	0.5	1
74	Influence of obesity on the incidence and treatment of genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 476-486.	1.6	37
75	Nutrigenetics and Prostate Cancer: 2011 and Beyond. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 121-136.	1.3	10

#	ARTICLE	IF	CITATIONS
76	Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer and Prostatic Diseases, 2011, 14, 340-345.	3.9	51
77	Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. Journal of Urology, 2011, 185, 2102-2107.	0.4	76
78	Obesity and prostate cancer collateral damage in the battle of the bulge. Frontiers in Bioscience - Scholar, 2011, S3, 594-605.	2.1	11
79	Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU International, 2011, 108, E77-83.	2.5	75
80	Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy?. Prostate Cancer and Prostatic Diseases, 2011, 14, 74-78.	3.9	38
81	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. British Journal of Cancer, 2011, 104, 875-881.	6.4	23
82	Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism: Clinical and Experimental, 2011, 60, 1234-1243.	3.4	51
83	The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes and Control, 2011, 22, 977-983.	1.8	47
84	Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested caseâ€“control study. Cancer Causes and Control, 2011, 22, 1121-1131.	1.8	42
85	Metabolic risk factors in prostate cancer. Cancer, 2011, 117, 2020-2023.	4.1	12
86	Prostate cancer risk in the Swedish AMORIS study. Cancer, 2011, 117, 2086-2095.	4.1	87
87	Association of diabetes mellitus with prostate cancer: Nested caseâ€“control study (Prostate testing) Tj ETQq1 1 0,784314 rgBT /Over	5.1	56
88	The association of weight gain during adulthood with prostate cancer incidence and survival: A populationâ€“based cohort. International Journal of Cancer, 2011, 129, 1199-1206.	5.1	23
89	Effect of Low-Fat Diets on Plasma Levels of NF-Î²Bâ€“Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer. Cancer Prevention Research, 2011, 4, 1590-1598.	1.5	48
90	Cancer Risk and Behavioral Factors, Comorbidities, and Functional Status in the US Elderly Population. ISRN Oncology, 2011, 2011, 1-9.	2.1	12
91	The Effects of Body Mass Index on Changes in Prostate-Specific Antigen Levels and Prostate Volume Over 15 Years of Follow-up: Implications for Prostate Cancer Detection. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 501-508.	2.5	32
92	Association of Obesity and Smoking With PSA and PSA Velocity in Men With Prostate Cancer. American Journal of Men's Health, 2011, 5, 272-278.	1.6	9
93	Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Annals of Oncology, 2011, 22, 801-807.	1.2	69

#	ARTICLE	IF	CITATIONS
94	Diabetes causes multiple genetic alterations and downregulates expression of DNA repair genes in the prostate. <i>Laboratory Investigation</i> , 2011, 91, 1363-1374.	3.7	18
95	Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. <i>British Journal of Cancer</i> , 2011, 105, 1061-1068.	6.4	46
96	Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis. <i>Cancer Prevention Research</i> , 2011, 4, 486-501.	1.5	398
97	Diabetes and prostate cancer risk in the REDUCE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 326-331.	3.9	52
98	Obesity and Prostate Cancer Aggressiveness among African and Caucasian Americans in a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 844-853.	2.5	44
99	The Impact of Diabetes Mellitus on Survival in Men With Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 572-579.	1.3	9
100	Body mass index and incidence of localized and advanced prostate cancer—a dose-response meta-analysis of prospective studies. <i>Annals of Oncology</i> , 2012, 23, 1665-1671.	1.2	229
101	Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 346-352.	3.9	91
102	Central Adiposity and Prostate Cancer in a Black Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 851-858.	2.5	22
103	Androgens, diabetes and prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, F47-F62.	3.1	66
104	Effect of Obesity on Serum Prostate-Specific Antigen in Nigerian Men. <i>Urologia Internationalis</i> , 2012, 89, 52-56.	1.3	8
105	The influence of antidiabetic medications on the development and progression of prostate cancer. <i>Cancer Epidemiology</i> , 2012, 36, e243-e250.	1.9	35
107	Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 735-743.	1.6	47
108	Effect of Diabetes Mellitus on High-grade Prostate Cancer Detection Among Japanese Obese Patients With Prostate-specific Antigen Less Than 10 ng/mL. <i>Urology</i> , 2012, 79, 1329-1335.	1.0	12
109	Editorial Comment. <i>Urology</i> , 2012, 79, 1334-1335.	1.0	0
111	Impact of Body Mass Index on Perioperative Morbidity, Oncological, and Functional Outcomes After Extraperitoneal Laparoscopic Radical Prostatectomy. <i>Urology</i> , 2012, 80, 576-584.	1.0	35
112	Diabetic nephropathy is associated with prostate-specific antigen levels in type 2 diabetes mellitus. <i>Cancer Causes and Control</i> , 2012, 23, 1875-1879.	1.8	1
113	The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. <i>Nutrition and Metabolism</i> , 2012, 9, 74.	3.0	50

#	ARTICLE	IF	CITATIONS
114	Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer and Prostatic Diseases, 2012, 15, 28-35.	3.9	37
115	Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 caseâ€“control and 25 cohort studies. Acta Diabetologica, 2012, 49, 235-246.	2.5	42
116	Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (â€“12)â€“core prostate biopsy. Prostate, 2012, 72, 51-57.	2.3	21
117	Weight change and prostate cancer incidence and mortality. International Journal of Cancer, 2012, 131, 1711-1719.	5.1	70
118	Obesity in Cancer Survival. Annual Review of Nutrition, 2012, 32, 311-342.	10.1	150
119	Diet and prostate cancer prevention. World Journal of Urology, 2012, 30, 157-165.	2.2	21
120	Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER- α and GPER signalling. Molecular and Cellular Endocrinology, 2012, 351, 269-278.	3.2	99
121	Obesity is associated with castrationâ€“resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU International, 2012, 110, 492-498.	2.5	82
123	Nutrition and Prostate Cancer. , 2013, , 673-695.		0
124	Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial. Journal of the National Cancer Institute, 2013, 105, 1132-1141.	6.3	263
125	Lifetime body size and prostate cancer risk in a population-based caseâ€“control study in Sweden. Cancer Causes and Control, 2013, 24, 2143-2155.	1.8	22
126	Diabetes mellitus and prostate cancer risk of different grade or stage: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2013, 99, 241-249.	2.8	54
127	Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy. International Urology and Nephrology, 2013, 45, 121-127.	1.4	11
128	Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients. Clinical Genitourinary Cancer, 2013, 11, 211-220.	1.9	17
129	Obesity and Prostate Cancer: Weighing the Evidence. European Urology, 2013, 63, 800-809.	1.9	458
130	The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study. Journal of Cancer Research and Clinical Oncology, 2013, 139, 943-951.	2.5	14
132	Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer and Prostatic Diseases, 2013, 16, 151-158.	3.9	155
133	Pleiotropy between Genetic Markers of Obesity and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1538-1546.	2.5	3

#	ARTICLE	IF	CITATIONS
134	Obesity and Future Prostate Cancer Risk among Men after an Initial Benign Biopsy of the Prostate. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 898-904.	2.5	20
135	The Impact of Obesity on Benign and Malignant Urologic Conditions. Postgraduate Medicine, 2013, 125, 53-69.	2.0	39
136	Diabetes Mellitus and Prostate Cancer Risk; A Nationwide Caseâ€“Control Study within PCBaSe Sweden. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1102-1109.	2.5	54
137	Diabetes predicts metastasis after radical prostatectomy in obese men: results from the <scp>SEARCH</scp> database. BJU International, 2013, 111, E310-8.	2.5	11
138	Body mass index influences prostate cancer risk at biopsy in <scp>J</scp>apanese men. International Journal of Urology, 2013, 20, 701-707.	1.0	16
139	Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested caseâ€“control studies. Prostate Cancer and Prostatic Diseases, 2013, 16, 352-356.	3.9	33
140	Overview of Obesity, Inflammation, and Cancer. , 2013, , 21-40.		0
141	CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis. Current Drug Safety, 2013, 8, 296-332.	0.6	52
142	Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget, 2013, 4, 2108-2123.	1.8	166
143	Prostate Cancer Disparities throughout the Cancer Control Continuum. Social Sciences, 2013, 2, 247-269.	1.4	5
145	The health consequences of obesity. , 2014, , 48-66.		1
147	Mechanisms Linking Excess Adiposity and Carcinogenesis Promotion. Frontiers in Endocrinology, 2014, 5, 65.	3.5	110
148	Grade 2 and 3 Obesity and Diagnosed Prostate Cancer in Middle-Aged and Elderly Men: An Epidemiologic Study with Stratified Multistage Sampling Design. ISRN Epidemiology, 2014, 2014, 1-7.	0.6	0
149	Â¿Es la obesidad un factor predictor de agresividad en cÃ¡ncer de prÃ³stata?. Revista Mexicana De Urologia, 2014, 74, 275-280.	0.0	1
150	Is There a Role for Body Mass Index in the Assessment of Prostate Cancer Risk on Biopsy?. Journal of Urology, 2014, 192, 1094-1099.	0.4	18
151	Type 2 Diabetes: A Protective Factor for Prostate Cancer? An Overview of Proposed Mechanisms. Clinical Genitourinary Cancer, 2014, 12, 143-148.	1.9	27
152	Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer and Metastasis Reviews, 2014, 33, 527-543.	5.9	87
153	Genderâ€“specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2014, 16, 276-283.	4.4	14

#	ARTICLE	IF	CITATIONS
154	Serum omentin level in patients with prostate cancer. Medical Oncology, 2014, 31, 923.	2.5	43
155	Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2936-2942.	2.5	84
156	Prevention and early detection of prostate cancer. Lancet Oncology, The, 2014, 15, e484-e492.	10.7	372
157	Obesity and Long-Term Survival after Radical Prostatectomy. Journal of Urology, 2014, 192, 1100-1104.	0.4	47
158	Association of body mass index and prostate cancer mortality. Obesity Research and Clinical Practice, 2014, 8, e374-e381.	1.8	37
159	Metformin Use and Prostate Cancer Risk. European Urology, 2014, 66, 1012-1020.	1.9	109
160	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	3.9	123
161	Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2015, 136, 372-381.	5.1	72
162	A High-Fat Diet Containing Lard Accelerates Prostate Cancer Progression and Reduces Survival Rate in Mice: Possible Contribution of Adipose Tissue-Derived Cytokines. Nutrients, 2015, 7, 2539-2561.	4.1	41
163	State of the art paper The impact of nutrition in urogenital cancers. Archives of Medical Science, 2015, 2, 411-418.	0.9	17
164	Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies. Oncology Letters, 2015, 9, 1307-1312.	1.8	78
165	Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prevention Research, 2015, 8, 737-742.	1.5	11
166	Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA Oncology, 2015, 1, 342.	7.1	70
167	Clinical performance of the Prostate Health Index (<scp>PHI</scp>) for the prediction of prostate cancer in obese men: data from the <scp>PROMetheus</scp> project, a multicentre <scp>E</scp>uropean prospective study. BJU International, 2015, 115, 537-545.	2.5	25
168	Nutrition, Lifestyle, and Obesity in Urology. , 2015, , 221-226.		0
169	The impact of obesity on prostate cancer recurrence observed after exclusion of diabetics. Cancer Causes and Control, 2015, 26, 821-830.	1.8	19
170	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616.	1.8	77
171	Obesity, Physical Activity and Bladder Cancer. Current Urology Reports, 2015, 16, 74.	2.2	26

#	ARTICLE	IF	CITATIONS
172	Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium. <i>American Journal of Epidemiology</i> , 2015, 182, 381-389.	3.4	42
173	Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: Results from the North-American case-control study Prostate Cancer & Environment Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 494.e1-494.e7.	1.6	40
174	Diabetes mellitus and the risk of prostate cancer: an update and cumulative meta-analysis. <i>Endocrine Research</i> , 2015, 40, 54-61.	1.2	53
175	Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 336-343.	4.0	54
176	Level-1 Data From the REDUCE Study and the PCPT Data. , 2016, , 199-203.		0
177	The Impact of Diabetes on the Risk of Prostate Cancer Development according to Body Mass Index: A 10-year Nationwide Cohort Study. <i>Journal of Cancer</i> , 2016, 7, 2061-2066.	2.5	20
178	Inflammation and Infection in the Etiology of Prostate Cancer. , 2016, , 13-20.		5
179	The Influences of Health Insurance and Access to Information on Prostate Cancer Screening among Men in Dominican Republic. <i>Journal of Cancer Epidemiology</i> , 2016, 2016, 1-11.	1.1	6
180	Body size across the life course and prostate cancer in the <sc>Health Professionals Follow-up Study. <i>International Journal of Cancer</i> , 2016, 138, 853-865.	5.1	48
181	The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. <i>BMC Cancer</i> , 2016, 16, 557.	2.6	12
182	Occupational risk factors for prostate cancer in an area of former coal, iron, and steel industries in Germany. Part 2: results from a study performed in the 1990s. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2016, 79, 1130-1135.	2.3	6
183	The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA. <i>International Urology and Nephrology</i> , 2016, 48, 1623-1629.	1.4	1
184	Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. <i>Cancer Medicine</i> , 2016, 5, 1307-1318.	2.8	46
185	Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment. <i>Tumor Biology</i> , 2016, 37, 14363-14380.	1.8	21
187	Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 353-357.	1.3	2
188	Prognostic Value of Leptin Receptor Overexpression in Upper Tract Urothelial Carcinomas in Taiwan. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e653-e659.	1.9	11
189	Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. <i>Scandinavian Journal of Urology</i> , 2017, 51, 5-12.	1.0	41
190	Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. <i>Scientific Reports</i> , 2017, 7, 43551.	3.3	10

#	ARTICLE	IF	CITATIONS
191	Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort. <i>Urology</i> , 2017, 105, 129-135.	1.0	16
192	Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer. <i>Aging Male</i> , 2017, 20, 257-260.	1.9	34
193	Quantifying the Genetic Correlation between Multiple Cancer Types. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1427-1435.	2.5	48
194	Metformin and cancer: An existing drug for cancer prevention and therapy (Review). <i>Oncology Letters</i> , 2018, 15, 683-690.	1.8	115
195	Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. <i>BMC Medicine</i> , 2017, 15, 115.	5.5	66
196	BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. <i>Oncotarget</i> , 2017, 8, 66051-66060.	1.8	14
197	A stage-dependent link between metabolic syndrome components and incident prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 321-333.	3.8	23
198	Energy Balance and Prostate Cancer. <i>Energy Balance and Cancer</i> , 2018, , .	0.2	0
199	Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. <i>Integrative Cancer Therapies</i> , 2018, 17, 1103-1108.	2.0	7
200	Mendelian randomization does not support serum calcium in prostate cancer risk. <i>Cancer Causes and Control</i> , 2018, 29, 1073-1080.	1.8	6
201	Diabetes mellitus and prostate cancer metabolism: Is there a relationship?. <i>Archivio Italiano Di Urologia Andrologia</i> , 2018, 90, 184-190.	0.8	4
202	Association of Anthropometric Measures with Prostate Cancer among African American Men in the NCI-Maryland Prostate Cancer Case-Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 936-944.	2.5	9
203	Concentrated sugars and incidence of prostate cancer in a prospective cohort. <i>British Journal of Nutrition</i> , 2018, 120, 703-710.	2.3	16
205	Body size and dietary risk factors for aggressive prostate cancer: a caseâ€“control study. <i>Cancer Causes and Control</i> , 2019, 30, 1301-1312.	1.8	2
206	Dietary palmitate cooperates with Src kinase to promote prostate tumor progression. <i>Prostate</i> , 2019, 79, 896-908.	2.3	13
207	Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship. <i>Medicina (Lithuania)</i> , 2019, 55, 62.	2.0	11
208	Incidence of Prostate Cancer according to Metabolic Health Status: a Nationwide Cohort Study. <i>Journal of Korean Medical Science</i> , 2019, 34, e49.	2.5	14
209	Prostate Cancer Disparity, Chemoprevention, and Treatment by Specific Medicinal Plants. <i>Nutrients</i> , 2019, 11, 336.	4.1	16

#	ARTICLE	IF	CITATIONS
210	The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 2218.	3.3	59
211	<p>Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis</p>. Cancer Management and Research, 2019, Volume 11, 10043-10050.	1.9	7
212	Serum insulin level, HOMA-IR and prostate cancer risk: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 110-115.	3.6	17
213	Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 66-76.	3.9	28
214	Lifestyle and Dietary Factors and Prostate Cancer Risk: A Multicentre Case-Control Study. Clinical Nursing Research, 2019, 28, 992-1008.	1.6	2
215	A methodology for detecting relevant single nucleotide polymorphism in prostate cancer with multivariate adaptive regression splines and backpropagation artificial neural networks. Neural Computing and Applications, 2020, 32, 1231-1238.	5.6	7
216	Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold. International Journal of Clinical Oncology, 2020, 25, 472-478.	2.2	12
217	Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer. Annals of Oncology, 2020, 31, 103-114.	1.2	35
218	Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer. Prostate International, 2020, 8, 22-26.	2.3	8
219	Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. JCO Global Oncology, 2020, 6, 1481-1489.	1.8	7
220	Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. PLoS ONE, 2020, 15, e0238928.	2.5	0
221	Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipocyte osteogenic balance in bone marrow. Cancer Science, 2020, 111, 3600-3612.	3.9	19
222	Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference. BMC Cancer, 2020, 20, 589.	2.6	13
223	Chronic Periodontal Disease increases risk for Prostate Cancer in Elderly individuals in South Korea: a Retrospective Nationwide Population-based Cohort Study. Journal of Cancer, 2020, 11, 4716-4723.	2.5	8
224	Oxidative stress and diabetes: antioxidative strategies. Frontiers of Medicine, 2020, 14, 583-600.	3.4	246
226	Waist circumference and a body shape index and prostate cancer risk and mortality. Cancer Medicine, 2021, 10, 2885-2896.	2.8	5
227	Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectrum, 2021, 5, pkab023.	2.9	13
228	Association of Anthropometric Measures With the Risk of Prostate Cancer in the Multiethnic Cohort. American Journal of Epidemiology, 2021, 190, 1770-1783.	3.4	2

#	ARTICLE	IF	CITATIONS
229	General and abdominal obesity trajectories across adulthood, and risk of prostate cancer: results from the PROtEuS study, Montreal, Canada. <i>Cancer Causes and Control</i> , 2021, 32, 653-665.	1.8	2
230	Visceral Adiposity and Cancer: Role in Pathogenesis and Prognosis. <i>Nutrients</i> , 2021, 13, 2101.	4.1	36
231	Initial Findings from a High Genetic Risk Prostate Cancer Clinic. <i>Urology</i> , 2021, 156, 96-103.	1.0	5
232	Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study. <i>Scientific Reports</i> , 2021, 11, 19266.	3.3	2
233	Genome-Scale CRISPR-Cas9 Transcriptional Activation Screening in Metformin Resistance Related Gene of Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 616332.	3.7	9
234	New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 439-446.	2.8	7
235	The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. , 2010, , 579-599.		4
236	Genetic Susceptibility and High Risk Groups for Pancreatic Cancer. , 2010, , 565-600.		1
237	Insulin, Insulin Resistance, and Cancer Associations. <i>Energy Balance and Cancer</i> , 2011, , 111-140.	0.2	3
238	Adiposity and Diabetes in Breast and Prostate Cancer. , 2013, , 33-51.		2
239	Overview of US Prostate Cancer Trends in the Era of PSA Screening. , 2009, , 3-14.		3
240	Energy Intake, Physical Activity, Energy Balance, and Cancer: Epidemiologic Evidence. <i>Methods in Molecular Biology</i> , 2009, 472, 191-215.	0.9	86
241	The Role of Nutrition and Diet in Prostate Cancer. , 2010, , 195-218.		2
243	Epidemiology, Etiology, and Prevention of Prostate Cancer. , 2012, , 2704-2725.e7.		12
244	The likelihood of having a serum PSA level of ≥ 2.5 or ≥ 4.0 ng mL ⁻¹ according to obesity in a screened Korean population. <i>Asian Journal of Andrology</i> , 2013, 15, 770-772.	1.6	5
245	Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. <i>PLoS Medicine</i> , 2016, 13, e1002118.	8.4	69
246	Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies. <i>PLoS ONE</i> , 2010, 5, e10858.	2.5	28
247	Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk. <i>PLoS ONE</i> , 2010, 5, e13485.	2.5	61

#	ARTICLE	IF	CITATIONS
248	Diabetes Protects from Prostate Cancer by Downregulating Androgen Receptor: New Insights from LNCaP Cells and PAC120 Mouse Model. PLoS ONE, 2013, 8, e74179.	2.5	22
249	Obesity Affects the Biopsy-Mediated Detection of Prostate Cancer, Particularly High-Grade Prostate Cancer: A Dose-Response Meta-Analysis of 29,464 Patients. PLoS ONE, 2014, 9, e106677.	2.5	41
250	Does Obesity Impact Treatment Outcome for Prostate Cancer Patients Treated with Radiotherapy: The Weighted Debate. Journal of Cancer Prevention & Current Research, 2014, 1, .	0.1	2
251	Correlation between body mass index (BMI) and the Gleason score of prostate biopsies in Chinese population. Oncotarget, 2016, 7, 63338-63341.	1.8	3
252	Bone marrow adipocytes promote the Warburg phenotype in metastatic prostate tumors via HIF-1 α activation. Oncotarget, 2016, 7, 64854-64877.	1.8	87
253	Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget, 2017, 8, 99093-99103.	1.8	8
254	Body mass index and incidence of nonaggressive and aggressive prostate cancer: a dose-response meta-analysis of cohort studies. Oncotarget, 2017, 8, 97584-97592.	1.8	15
255	Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget, 2018, 9, 34485-34494.	1.8	33
256	Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian Journal of Urology, 2010, 26, 502.	0.6	19
257	Clinical and biochemical markers of visceral adipose tissue activity: Body mass index, visceral adiposity index, leptin, adiponectin, and matrix metalloproteinase-3. Correlation with Gleason patterns 4 and 5 at prostate biopsy. Urology Annals, 2018, 10, 280.	0.6	6
258	The Effect of BMI and Visceral Fat Percentage on the Development of Bone Metastases in Prostate Cancer. Journal of Nuclear Medicine & Radiation Therapy, 2014, 05, .	0.2	1
259	Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis. Central European Journal of Urology, 2013, 66, 423-7.	0.3	9
260	Diabetes Mellitus Reduces Prostate Cancer Risk - No Function of Age at Diagnosis or Duration of Disease. Asian Pacific Journal of Cancer Prevention, 2013, 14, 441-447.	1.2	11
261	Prostate Cancer Incidence in Turkey: An Epidemiological Study. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9125-9130.	1.2	23
262	Diabetes Mellitus and HbA1c Levels Associated with High Grade Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2555-2558.	1.2	13
263	RELACIÓN ENTRE EL ÍNDICE DE MASA CORPORAL Y LA DETECCIÓN DE CÁNCERES PROSTÁTICOS EN LA CIRCULACIÓN SANGUÍNEA (CPCS) EN HOMBRES SANOS: UN ESTUDIO PILOTO. Revista Chilena De Nutrición, 2007, 34, .	0.3	0
264	Obesity and Cancer. , 2008, , 196-215.		0
265	Molecular Mechanisms of Obesity, Inflammation and Cancer: The Use of in vitro Model Approaches for Targeted Prevention Strategies. The Open Obesity Journal, 2010, 2, 23-37.	0.1	0

#	ARTICLE	IF	CITATIONS
266	Alternative Medicine for Prostate Cancer: Diet, Vitamins, Minerals, and Supplements. , 2010, , 207-228.		0
267	The Role of Obesity and Diet in Prostate Cancer. , 2012, , 127-142.		0
268	Obesity in the Elderly “ On the Role of Adipokines in Prostate Cancer Progression. European Oncology and Haematology, 2012, 08, 46.	0.0	0
269	Epidemiology and Prevention of Prostate Cancer. , 2013, , 3-31.		0
270	Prevention of Prostate Cancer. , 2014, , 491-531.		0
271	Malignant Tumors of the Male Reproductive System. , 2014, , 423-437.		0
273	Abstract 880: Obesity predicts prostate cancer-specific mortality after radical prostatectomy: Results from the SEARCH database. , 2015, , .		0
274	Obesity as a risk factor for prostate cancer: A clinical review. Integrative Cancer Science and Therapeutics, 2016, 3, .	0.1	1
275	Consequence of Energy Imbalance in Prostate Cancer and Comorbidities. Energy Balance and Cancer, 2018, , 43-70.	0.2	0
276	Adipokines and Prostate Cancer. Energy Balance and Cancer, 2018, , 71-86.	0.2	0
277	Epidemiology and Etiology. Molecular Pathology Library, 2018, , 13-26.	0.1	0
279	Therapeutic role of metformin and troglitazone to prevent cancer risk in diabetic patients: evidences from experimental studies. Turkish Journal of Biochemistry, 2020, 45, 229-239.	0.5	0
280	Dr. Answer AI Software for Prostate Cancer: Explainable Variable Importance of Predicting T Stage. , 2020, , .		0
281	Metabolic imbalance and prostate cancer progression. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 248-71.	0.4	11
282	The pathophysiology of obesity and its clinical manifestations. Gastroenterology and Hepatology, 2007, 3, 856-63.	0.1	42
283	Prostate Cancer Related JAZF1 Gene is Associated with Schizophrenia. Journal of Schizophrenia Research, 2014, 1, .	1.0	2
284	Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer. Metabolites, 2021, 11, 765.	2.9	21
285	Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. Frontiers in Oncology, 2021, 11, 808715.	2.8	4

#	ARTICLE	IF	CITATIONS
286	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. <i>Cancer Causes and Control</i> , 2022, 33, 429-440.	1.8	3
287	Association of Obesity and Diabetes With Prostate Cancer Risk Groups in a Multiethnic Population. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 299-299.e10.	1.9	9
288	Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. <i>Endocrine-Related Cancer</i> , 2022, 29, 99-109.	3.1	8
289	Somatic mutational profiles and germline polygenic risk scores in human cancer. <i>Genome Medicine</i> , 2022, 14, 14.	8.2	14
290	The Effectiveness of Pelvic Floor Muscle Training in Men after Radical Prostatectomy Measured with the Insert Test. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 2890.	2.6	6
291	Differential Biopsy Patterns Influence Associations Between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	2.5	1
292	Obesity and prostate cancer. , 2023, , 115-128.		0
294	Risk analysis of metformin use in prostate cancer: a national population-based study. <i>Aging Male</i> , 2023, 26, .	1.9	0
295	Diabetes and Cancer. <i>Journal of Korean Diabetes</i> , 2023, 24, 12-17.	0.3	0
296	Obesity and prostate cancer “microenvironmental roles of adipose tissue. <i>Nature Reviews Urology</i> , 2023, 20, 579-596.	3.8	5
297	Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1208-1216.	2.5	0
298	Adiposity and sex-specific cancer risk. <i>Cancer Cell</i> , 2023, 41, 1186-1197.e4.	16.8	5
299	Obesity and prostate cancer screening, incidence, and mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Journal of the National Cancer Institute</i> , 2023, 115, 1506-1514.	6.3	5
300	Diabetes mellitus and cancer. <i>Cardiovascular Prevention and Pharmacotherapy</i> , 0, , .	0.1	0